Fulltext

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

Ooi CJ 1 , Hilmi I , Banerjee R 2 , Chuah SW 3 , Ng SC 4 , Wei SC 5 Show all authors , Makharia GK 6 , Pisespongsa P 7 , Chen MH 8 , Ran ZH 9 , Ye BD 10 , Park DI 11 , Ling KL 12 , Ong D 13 , Ahuja V 5 , Goh KL 14 , Sollano J 15 , Lim WC 16 , Leung WK 17 , Ali RAR 18 , Wu DC 19 , Ong E 15 , Mustaffa N 20 , Limsrivilai J 21 , Hisamatsu T 22 , Yang SK 23 , Ouyang Q 24 , Geary R 25 , De Silva JH 26 , Rerknimitr R 27 , Simadibrata M 28 , Abdullah M 29 , Leong RW 30 , Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis 1

Affiliations 

  • 1 Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore
  • 2 Asian Institute of Gastroenterology, New Delhi, India
  • 3 Gleneagles Medical Centre, Singapore
  • 4 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
  • 5 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • 6 Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India
  • 7 Gastroenterology and Hepatology, Bumrungrad International University, Bangkok, Thailand
  • 8 Division of Gastroenterology, The First University Hospital, Sun Yat-sen University, Guangzhou, China
  • 9 Department of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  • 10 Department of Gastroenterology and IBD Center, University of Ulsan College of Medicine, Seoul, Korea
  • 11 Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
  • 12 Duke-NUS Medical School, Singapore
  • 13 Division of Gastroenterology and Hepatology, National University Hospital of Singapore, University Medicine Cluster, Singapore
  • 14 University of Malaya Specialist Centre, Kuala Lumpur, Malaysia
  • 15 Department of Medicine, University of Santo Tomas, Manila, Philippines
  • 16 Department of Gastroenterology and Hepatology, Tan Tock Seng Hospital, Singapore
  • 17 Division of Gastroenterology and Hepatology, Department of Medicine, University of Hong Kong, Hong Kong
  • 18 Faculty of Medicine, UKM Medical and Specialist Centres, The National University of Malaysia, Kuala Lumpur, Malaysia
  • 19 Department of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
  • 20 Department of Internal Medicine, School of Medical Sciences, Health Campus, Sains University, Kubang Kerian, Malaysia
  • 21 Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 22 The Third Department of Internal Medicine, Kyorin University School of Medicine, Mitaka, Japan
  • 23 Department of Gastroenterology, University of Ulsan College of Medicine, Seoul, Korea
  • 24 Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China
  • 25 Department of Medicine, University of Otago, Christchurch, New Zealand
  • 26 Faculty of Medicine, University of Kelaniya, Dalugama, Sri Lanka
  • 27 Department of Medicine, Chulalongkorn University, Bangkok, Thailand
  • 28 Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
  • 29 Division of Gastroenterology, Department of Internal Medicine, Cipto Mangunkusumo National Hospital, Jakarta, Indonesia
  • 30 Gastroenterology and Liver Services, Concord Hospital, Sydney, Australia
Intest Res, 2019 Jul;17(3):285-310.
PMID: 31146509 DOI: 10.5217/ir.2019.00026

Abstract

The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn's disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications